Oxford Cancer Biomarkers is an Oxford-based biomarker company that is commercializing biomarker tests for colorectal cancer testing.
Oxford Cancer Biomarkers was created by University of Oxford cancer professors, Nick La Thangue and David Kerr to transform personalised medicine using biomarker technology. Its current tests focus on colorectal cancer diagnosis, management and treatment, and it aims to expand its portfolio of tests to serve as benefit for other cancer treatment programmes.
Oxford Cancer Biomarkers aims to enable early prediction of cancer risk and increased precision of cancer treatment to drive personalized medicine. It does this via the use of platforms that are incorporating biomarker-based technology from its research and development teams and partners.